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Background: Osteoporotic fractures and falls are as heads and tails of
a coin. Among the elderly, the greatest risk of fracture comes from
falls, rather than osteoporosis, hence, bone mineral density measure-
ment should not be used alone to estimate fracture risk or guide
treatment decisions. Evidence shows that at least 15% of falls in older
people can be prevented, with individual trials reporting relative
reductions of up to 50%. We developed a model that predicts the falls
risk among patients referred for bone mineral density using variables
that are easily assessed in clinical practice.
Methods: As part of the integrated osteoporosis and falls service,
patients admitted to the hospital with low trauma fracture had
their bone mineral density assessed. In addition to DXA scanning,
fracture risk assessment using FRAX (before and after the occurrence
of the fracture), as well as falls risk factors were analyzed. The
independent predictive value of the different risk factors for the
occurrence of falls was assessed using logistic regression analysis.
A prediction scoring system was developed using data from a cohort
of 106 patients. 102 osteoporotic patients without history of falls or
fracture were also assessed as control group. The diagnostic
performance of the prediction model was evaluated using the area
under the curve (AUC). The developed prediction model was internally
validated.
Results: Falls risk was significantly higher among the osteoporotic
patients who sustained fractures in comparison to the control group
(P<0.01). The risk factors significantly correlated with an increased
risk of falls were: history of >1 fall in the last 12 months (regression
coefficient 2.2), slowing of the walking speed/ change of the gait (1.6),
impaired vision (1.2), weak grip strength (1.1), loss of balance (1.2). Cut
off point of 3.5 achieved the best sensitivity and specificity (0.918 and
0.86 respectively, PPV85.9) and was indicative of high falls risk. A
score of 2.0-3.5 was indicative of moderate risk.
Conclusions: The findings indicate that evaluation of falls risk based
on risk factor profiles of individual patients can help physicians identify
high risk osteoporotic patients and assist with decisions concerning
falls prevention and patient management. Also, these results empha-
size the importance of performing a falls risk assessment for all
osteoporotic patients, in parallel with bone mineral density measure-
ment, on regular basis as part of their assessment and management.
Disclosure statement: All authors have declared no conflicts of
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142. BENEFIT OF USING FRAX TO TARGET DXA USE IN A
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Amada Aguye2, Marta Zwart2,4 and Kassim M. Javaid1
1Rheumatology, NIHR Musculoskeletal BRU, University of Oxford,
Oxford, UK; 2Primary Health Care, IDIAP Jordi Gol. Institut Catala de
la Salut, Barcelona, Spain; 3Nuclear Medicine / DXA, Hospital
Universitari Vall d’Hebron, Barcelona, Spain; 4Internal Medicine,
Universitat Autonoma de Barcelona, Barcelona, Spain
Background: Assessment (AT) and intervention thresholds (IT) and
management algorithms have been proposed for the UK based on
fracture probability from FRAX. A version of it is available for the
Spanish population, which we applied, using the UK AT, IT and
algorithms, in a sample from Barcelona (Spain) to assess the effect of
FRAX in reducing the number of DXA requested.
Methods: The FRIDEX database at the Vall d’Hebron Hospital
(Barcelona) includes all patients who underwent DXA scanning from
1999. At the time of scanning, questionnaires were administered: age,
fractures, smoking, alcohol, family history of hip fracture (HF),
rheumatoid arthritis, other secondary causes of osteoporosis and
steroid exposure was collected. Height and weight were measured.All
patients then underwent DXA measurement using a Lunar GE
‘‘Prodigy Advance’’. We used the NOGG UK FRAX to classify patients
into low, intermediate and high risk before and after DXA.
Results: 1,353 postmenopausal women, 50 years,consecutively
attended the DXA department (June/2008-May/2009), referred by their
GP or an specialist. Mean age: 65.47 yrs  9.31, weight: 67.80 37.32
kg and height: 156.1239.73cms. 159 (11.8%) women had
Osteoporosis (OP) at Femoral Neck, and 853 (65.8%) had
Osteopenia (T<1.5).
358 (25.7%) had a prior fracture at baseline. 56 (4.0%) had a family
antecedent of HF, 104 (7.5%) were smokers and none drank 3
alcohol units per day. 23 (1.7%) suffered from Rheumatoid Arthritis
and 7 (0.5%) from any other condition considered as cause of
Secondary OP in FRAX. 61 women (4.5%) had been exposed to oral
corticoids and 458 (32.9%) to anti-resortive drugs.
The median HF probability before DXA was 0.92.9 and 0.7 3.0
afterwards. Other major fracture probability was 4.35.3 and
4.05.1 after DXA.
Using hip risk probability AT, 18 women changed from low to high
risk after DXA and 23 changed from high to low risk. According to other
major fractures risk probabilities, only 2 (0.2%) women changed from
low to high risk and only 4 were considered as high risk before DXA;
from these, 2 changed from high risk pre-DXA to low risk.
Conclusions: The use of FRAX would have saved 992 DXA scans and
is a useful clinical tool to predict osteoporosis in the Spanish
population.
Disclosure statement: All authors have declared no conflicts of
interest.
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143. KNEE JOINT IN JIA: A PROSPECTIVE EVALUATION OF
CLINICAL EXAMINATION, ULTRASOUND AND MRI
ASSESSMENT. A NEWLY DEVELOPED KNEE MRI SCORING
SYSTEM IN JIA
Laura Pascoli1, Noel J. Napier1, Maria Wray1, Maura Mc Carron1,
Catherine Mc Allister1 and Madeleine E. Rooney2
1Musgrave Park Hospital - Belfast Hospital Trust, Belfast, UK;
2Queen’s University of Belfast, Belfast, UK
Background: We prospectively compared agreement between
clinical, ultrasound (US) and MRI assessments of the knee joints in
children with juvenile idiopathic arthritis (JIA).
Methods: Three hundred and thirty one knees from 48 children over
a period of 2 years, affected by JIA with knee arthritis, were
assessed clinically and ultrasonographically on the same day, using
a semi-quantitative scoring system from 0 to 3 (0: normal; 1: mild; 2:
moderate; 3: marked) for swelling and effusion, respectively.
A subgroup of these children (25) with a total of 40 knees had
matching MRI scans obtained within 0 to 14 days from clinical and US
examinations. For those, US and MRI scans (T1 weighted images)
were scored 0-3 for effusion, synovial hypertrophy, bone oedema and
bone erosions, using for the first time our newly developed knee
MRI scoring system.
Results: A moderate agreement for effusion was found between the
331 knees assessed clinically and ultrasonographically (linear
weighted Kappa: 0.54). Out of the 260 clinical normal knees, 30
(11.5%) had mild to moderate effusion on US and 89 (34.2%) had trace
Proportion of women eligible for BMD and for treatment, according to the algorithms proposed for women from the UK.
N Prior
fracture (%)
> AT and < IT (n, %) At least 1
Risk Factor (a)
Total eligible for
assessment (n; %)
[>AT,<IT or at least 1
Risk Factor] (a)
> IT after DXA
(n; %)
>1 Risk Factor
(n; %)
Total eligible
for treatment (n; %)
[Prior Fracture
or > T]
Major Hip Major Hip Major Hip Major Hip
50-54 years 173 28 (16.0%) 4 (2.3%) 36 (24.5%) 24 (14.0%) 36 (24.5%) 38 (25.9%) 2 (1.2%) 14 (8.1%) 37 (21.1%) 28 (16.2%) 35 (20.2%)
55-59 years 204 45 (17.4%) 2 (0.8%) 43 (20.2%) 17 (6.6%) 43 (20.2%) 44 (20.7%) 6 (2.3%) 14 (5.5%) 52 (20.2%) 47 (23.0%) 47 (23.0%)
60-64 years 277 71 (25.6%) 6 (2.2%) 25 (12.1%) 11 (4.0%) 25 (12.1%) 26 (12.6%) 1 (0.4%) 11 (4.0%) 78 (28.2%) 71 (25.6%) 74 (26.7%)
65-69 years 206 54 (25.8%) 3 (1.5%) 9 (5.8%) 9 (4.4%) 9 (5.8%) 10 (6.5%) 5 (2.5%) 16 (7.8%) 59 (28.2%) 54 (26.2%) 59 (28.6%)
70-74 years 177 42 (23.0%) 30 (17.2%) 12 (8.5%) 57 (32.8%) 12 (8.5%) 37 (26.2%) 1 (0.6%) 7 (4.0%) 46 (25.1%) 42 (23.7%) 46 (26.0%)
75-79 years 183 71 (37.6%) 58 (32.4%) 4 (3.4%) 69 (38.5%) 4 (3.4%) 23 (19.5%) 4 (2.2%) 20 (11.2%) 78 (41.3%) 72 (39.3%) 78 (42.6%)
80 years 97 47 (46.1%) 37 (40.2%) 3 (5.5%) 29 (31.5%) 3 (5.5%) 13 (23.6%) 3 (3.3%) 9 (9.8%) 49 (48.0%) 47 (48.5%) 49 (50.5%)
TOTAL 1,353 358 (25.7%) 140 (10.3%) 132 (12.8%) 216 (16.0%) 132 (12.8%) 191 (18.5%) 22 (1.6%) 91 (6.7%) 399 (28.6%) 361 (27.4%) 388 (29.5%)
(a) Excludes women with a prior fracture
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of effusion. In the subgroup of 40 knees that had matching US and MRI
scans it was demonstrated a good agreement for effusion (linear
weighted Kappa: 0.66) and a moderate agreement for synovial
hypertrophy (linear weighted Kappa: 0.47). The inter-observer US
agreement was very good for effusion (linear weighted kappa: 0.87)
and good for synovial hypertrophy (linear weighted kappa: 0.68). The
intra-observer MRI agreement was good for effusion (linear weighted
kappa: 0.73) and very good for synovial hypertrophy (linear weighted
kappa: 0.85).
Conclusions: A significant number of knee joint effusions are missed
on clinical examination. Musculoskeletal US is a simple, cheap, non
invasive, rapid and effective method of detecting joint synovitis in JIA
and should be used: as an adjunct to clinical examination especially
when joint injections are being considered and to avoid under-
diagnosis; when clinical examination is negative and symptoms are
equivocal for active arthritis; to identify the site for the intra-articular
injection; at follow-up to assess treatment’s efficacy. In our experience
it is also very well tolerated by children. Normal data on Paediatric
knees are needed to demonstrate whether a small amount of synovial
fluid is present.
Comparison between clinical and US scores (0-3) for swelling and effusion
respectively
US EFFUSION SCORE CLINICAL SWELLING SCORE
0 1 2 3
0 230 5 0 0
1 25 27 7 0
2 5 2 12 8
3 0 0 3 7
Disclosure statement: All authors have declared no conflicts of
interest.
144. INCREASED VITAMIN D BINDING PROTEIN
EXPRESSION IN JIA PATIENTS SUFFERING DISEASE
EXTENSION
David S. Gibson1, Laura Pascoli1, Catherine McAlilister1,
Caitriona Scaife2, Michael Dunn2, Stephen Pennington2 and
Madeleine Rooney1
1Arthritis Research Group, Queen’s University Belfast, Belfast, UK;
2Proteome Research Centre, University College Dublin, Dublin,
Ireland
Background: Juvenile idiopathic arthritis (JIA) comprises a poorly
understood group of chronic, childhood onset, autoimmune diseases
with variable clinical presentations, outcomes and therapeutic
responses. Current laboratory tests are unable to flag those patients
at a higher risk of disease spread to multiple joints, who could benefit
form earlier therapy to prevent joint damage. This study was focused
on profiling the synovial fluid (SF) proteome associated with disease
extension from oligo- to polyarticular status by a difference gel
electrophoresis (DIGE) approach.
Methods: To construct a discriminant model, SF samples from 55 JIA
patients were analysed: 30 oligo-, 8 extended oligo- and 17
polyarticular disease. Initial SF samples from each patient were
labeled with Cy dyes and subjected to protein separation by 2-DE. The
ability to distinguish patients at risk of disease extension by a select
group of proteins was illustrated by multivariate analysis methods.
Proteins over expressed with a two-fold difference between patient
subgroups were identified by MALDI-TOF. Specific antibodies were
used to validate putative biomarker expression in synovial fluid by
western immunoblotting and in synovial membrane (SM) by
immunohistochemistry.
Results: Samespots software analysis of SF gel scans was used to
highlight joint-specific proteins which were differentially expressed
across disease classifications. Hierarchical clustering based on the
expression levels of a previously selected set of 40 proteins matched
across the three clinical subgroups segregates the extended oligoarti-
cular patients. Proteolytic fragments of apolipoprotein AII, complement
component C3c and vitamin D binding protein were identified
(P<0.05) amongst the discriminatory proteins. Apolipoprotein AII
and vitamin D binding protein were expressed at significantly higher
levels in the polyarticular patients, P¼0.046 and P¼ 0.019 respec-
tively, both with a perivascular distribution in the SM.
Conclusions: Synovial fluid proteome profiles have been used to flag
JIA patients at risk of disease spread. The panel of identified proteins
may play a role in spread of joint inflammation. With further validation,
these putative prognostic biomarkers could improve the clinical
management of patients
Disclosure statement: All authors have declared no conflicts of
interest.
145. A PROSPECTIVE EVALUATION OF CLINICAL AND
ULTRASOUND FINDINGS IN ANKLE DISEASE IN JUVENILE
IDIOPATHIC ARTHRITIS
Laura Pascoli1, Stephen Wright1, Catherine Mc Allister1 and
Madeleine E. Rooney2
1Musgrave Park Hospital - Belfast Hospital Trust, Belfast, UK;
2Queen’s University of Belfast, Belfast, UK
Background: Intra-articular corticosteroid (IAC) injections are fre-
quently used by clinicians in the management of joint disease in JIA
with good effect. However, remarkably little has been written about the
effectiveness of IAC injection in ankle disease in JIA. Our experience
and of others, is that the response for ankle disease is disappointing.
The poor result from IAC injection may be due to the incorrect
identification of the structures involved. We compared prospectively
clinical examination of the ankle structures with ultrasound (US)
findings.
Methods: In 42 children with JIA (F/M¼ 25/17, mean age 11.3 years,
range 2.3-22.3), a total of 61 swollen/painful ankles were assessed
clinically and ultrasonographically. An accurate clinical examination of
the entire ankle joint, focusing especially on 3 regions - main ankle joint
(tibiotalar joint), medial tendons (tibialis posterior tendon group) and
lateral tendons (peroneal tendons) - has been performed. US images
were obtained by longitudinal and transverse scans with knee in
45 degrees of flexion. Clinical and US findings were both scored 0-3
(0: normal; 1: mild; 2: moderate; 3: severe). Involvement of other
structures such as talonavicular, tibialis anterior and subtalar involve-
ment was recorded.
Results: US demonstrated no signs of tibiotalar joint effusion in 14 out
of 43 ankles considered clinically involved. For the medial tendons, US
showed tenosynovitis in 13 ankles out of 31 thought to be clinically
normal; and for the lateral tendons, of the 19 deemed to be clinically
involved, less than 50% had involvement on US. Very poor agreement
was observed comparing the clinical and US scores for the 3 regions:
tibiotalar joint - kappa 0.3; medial tendons - kappa 0.24; lateral
tendons - kappa 0.25. With regards to other ankle structures, only 39%
of the subtalar joint considered clinically involved were deemed
abnormal on US. Finally, of the 10 ankles with talonavicular
ultrasonographical effusion, only 2 were considered to be clinically
involved. Of interest, from the US scans, in only 12 ankles (19.7%) the
tibiotalar joint was involved alone, whereas in 37 ankles (60.7%) both
the tibiotalar and tendons were involved. Conversely, in 10 ankles
(16.4%) tendons alone were involved.
Conclusions: This is the first prospective assessment of ankle disease
in JIA. Clinical examination of the ankle region in children with JIA is
inadequate in identifying the structures involved. US assessment on
that area prior to any therapeutically intervention should be considered
to improve the outcome.
Table. Agreement between involved vs non-involved according to the clinical and
US findings.
Clinical
normal /
US normal
Clinically
normal /
US abnormal
Clinically
abnormal /
US normal
Clinically
abnormal /
US abnormal
Tibiotalar joint 18 / 10 18 / 8 43 / 14 43 / 29
Tibialis post tendon group 31 / 18 31 / 13 30 / 11 30 / 19
Peroneal Tendons 42 / 33 42 / 9 19 / 11 19 / 8
Disclosure statement: All authors have declared no conflicts of
interest.
146. ASSOCIATION OF ERAP1 WITH ENTHESITIS RELATED
ARTHRITIS
Anne Hinks1, Paul Martin1, Edward Flynn1, Steve Eyre1,
Jon Packham2, Anne Barton1, Jane Worthington1 and
Wendy Thomson1
1arc Epidemiology Unit, University of Manchester, Manchester, UK;
2Haywood Hospital, University Hospital of North Staffordshire, Stoke
on Trent, UK
Background: The endoplasmic reticulum aminopeptidase 1 (ERAP1)
gene, formerly known as ARTS1, shows robust association with
ankylosing spondylitis (AS). HLA-B27 plays a central role in the
pathogenesis of many spondyloarthropathies and in particular AS. The
enthesitis related arthritis (ERA) subtype of juvenile idiopathic arthritis
(JIA) is characterized the association of enthesitis and arthritis. It may
go on to affect the sacroiliac and spinal joints, with symptoms similar
to AS. It mainly affects male individuals and most patients are HLA-
B27 positive. The aim of this study was to test whether ERAP1, the
confirmed AS susceptibility locus, also predisposes to the ERA
subtype of JIA.
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Methods: The SNP, rs30187, a non-synonymous SNP in the ERAP1
gene was genotyped in JIA cases (n¼1054) and healthy controls
(n¼ 2390). Genotype and allele frequencies were compared between
cases with JIA and controls using the Cochrane-Armitage trend test
implemented in PLINK and allelic odds ratios (ORs) and their 95%
confidence intervals (CIs) calculated. Allele frequency differences
between the seven ILAR subtypes were assessed using 2 tests on
the 7 x 2 tables.
Results: The SNP in the ERAP1 gene, rs30187, was not significantly
associated with JIA overall (ptrend¼0.73 OR 1.03 95% CI 0.92-1.14).
The SNP showed significant allele frequency differences (P¼ 0.01)
between the ILAR subtypes. Reanalysis of the SNP stratifying by
subtype found that the difference was driven by the association of the
enthesitis related arthritis (ERA) subtype with rs30187 (ptrend¼ 0.003
OR 1.7 95% CI 1.19-2.44). None of the other subtypes showed
evidence for association with the SNP.
Conclusions: We present subtype specific association of the ERAP1
gene and ERA, none of the other subtypes showed association with
the SNP. This finding will require validation in independent JIA data
sets. ERAP1 encodes a multifunctional aminopeptidase, but the
mechanism by which it affects disease risk is yet to be determined.
It may play a role in trimming peptides before loading into nascent HLA
class I molecules, or alternatively through its function in cleaving pro-
inflammatory cytokine receptors, such as TNFR1, IL1R2 and IL6R,
from the cell wall.
Disclosure statement: All authors have declared no conflicts of
interest.
147. USE OF BIOLOGIC AGENTS IN ADULTS WITH JUVENILE
IDIOPATHIC ARTHRITIS
Flora McErlane1, Priyanka Kulkarni2, Karl Nicholl1 and Helen
E. Foster1,2
1Paediatric Rheumatology, Royal Victoria Infirmary, Newcastle upon
Tyne, UK; 2Musculoskeletal Research Group, Newcastle University,
Newcastle upon Tyne, UK
Background: Biologic agents are increasingly used in rheumatological
practice although only etanercept and adalimumab have JIA as a
licensed indication in children. NICE guidance exists for etanercept in
polyarticular JIA but is limited to 4-17 year olds. Over one third of
children with JIA will continue to have active disease into their adult
years [1] and many will transfer to adult services with an ongoing need
for biologics. Furthermore, patients with JIA may develop new flares of
disease in their adult years requiring immunosuppression. No
guidance exists for the use of biologic agents in adults with JIA. Our
aim was to describe our experience of biologic use in a previously
described adult JIA population [2].
Methods: This retrospective case notes audit describes the use of
biologic therapy in an adult JIA clinic set up in 1996. A piloted
proforma based on NICE guidance for etanercept in JIA was used to
collect data on demographics, disease duration, disease modifying
drugs and biologics, adverse events and changes in treatment. The
study had Trust approval and was registered as an audit of clinical
practice.
Results: 31/184 patients (17%) have received biologic therapies to
date. Details were available for 27/31 patients; 19/27 (70%) were
female with a median age of 27 years (range 18 - 49), median age of
disease onset of 10.5 years (range 1 - 16) and a predominance of poly
JIA (16/27 (59%)). The median disease duration prior to first biologic
was 15 years (range 1 - 36); 6 patients (22%) were <16 and 21 (78%)
>16 years when the first biologic was commenced. All paediatric
cases were recorded on the BSPAR Biologics Registry and many adult
patients on the BSRBR. In 25/27 cases the first agent was etanercept
and in 2/27 infliximab (for active uveitis). Indications for use of
etanercept included persistent active disease (> 5 joints) and failure /
intolerance to methotrexate as per NICE guidance. 11/27 (41%)
patients switched to a second anti-TNF (8/11 with poly JIA) with
median time to switch 2.5 years (range 0.3 - 5.25). Initial switch was
due to waning of response in 9/11, often after protracted remission,
uveitis flare n¼1 and infusion reaction n¼1. Further switches of
biologic agent were required in 6/27 (22%) patients (lack of response
n¼ 5, uveitis flare n¼ 1).
Conclusions: Many adults with JIA have ongoing medical needs
associated with persistently active disease requiring immunosuppres-
sion, including continued use of biologics in adulthood and de novo
disease flares in adulthood. Adults with active JIA in this centre are
managed according to NICE guidance for poly JIA in children.
Guidance for the adult age group is clearly required. A waning of
initially good response was noted in this group, necessitating switch-
ing to alternative agents. This highlights the need for long-term efficacy
and safety studies in JIA, extending from childhood into adulthood.
A survey of clinical practice in other UK units with adult JIA clinics is
planned.
Disclosure statement: All authors have declared no conflicts of
interest.
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148. WORKFORCE PLANNING IN PAEDIATRIC
RHEUMATOLOGY IN THE UNITED KINGDOM (UK)
Clare Pain1, Eileen Baildam1, Helen Foster3, Mark Harrison2 and
Deborah Symmonds2
1Paediatric Rheumatology, Royal Liverpool Children’s Hospital,
Liverpool, UK; 2arc Epidemiology Unit, Manchester University,
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Background: The British Society for Paediatric and Adolescent
Rheumatology (BSPAR) recommends that all children with rheumatic
disease are managed by specialist multidisciplinary teams with
appropriate training in paediatric rheumatology (PRh) [1]. In the UK
and many other parts of the world, adult rheumatologists have
historically provided clinical care for children with rheumatic disease
and increasingly there has been development of multidisciplinary PRh
services working in clinical networks with adult rheumatologists or
paediatricians. Recent changes in clinical training in the UK have
resulted in PRh becoming a paediatric sub-speciality. Adult rheuma-
tology trainees are no longer being trained in PRh and will be ill-
equipped to manage children when incumbent adult rheumatology
specialists retire.
Methods: In 2007 a questionnaire was sent to all UK adult
rheumatology specialists. One aim was to identify the number of
adult rheumatologists seeing children under 16 years, describe the
clinical setting for consultations and to estimate numbers due to retire
based on a retirement age of 65 years. This information will be used to
determine future numbers of PRh consultants.
Results: The questionnaire was sent to 584 adult rheumatology
specialists with 403 (69%) responding to questions about PRh service
provision. 75/403 (19%) reported seeing patients aged under 16. The
median (IQR) number of patients seen per month was 10 (6, 15),
accounting for 931 paediatric patients seen in a year. Many
rheumatologists will retire in the next 5 and 10 years (13/73 (18%)
and 35/73 (48%) respectively). The majority (58/75, 78%) of respon-
dents hold separate clinics for all paediatric patients, often alongside
another health care professional (38/58 [57%] consultant paediatrician,
5/58 [9%] PRh specialist, 5/58 [9%] with both present and 7/58 [12%]
with another healthcare professional). 3/58 (5%) of adult rheumatol-
ogists ran paediatric clinics without another healthcare professional
present and 4/75 (5%) of all specialists seeing children did so on their
own without paediatric input.
Conclusions: Throughout the UK many adult rheumatologists are
involved in managing children with rheumatic disease and many within
a shared care model with paediatric rheumatologists or paediatricians.
Over the next 10 years a large number of adult rheumatologists who
manage children with rheumatic disease will retire. Their departure will
result in a large shortfall in service provision. Unless addressed
urgently in workforce planning and training within PRh in the UK, along
with appropriate expansion of clinical services, these changes will
results in marked inequity of access to specialist care for children with
rheumatic disease.
Disclosure statement: All authors have declared no conflicts of
interest.
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149. INVESTIGATION OF TYPE 1 DIABETES AND CELIAC
DISEASE SUSCEPTIBILITY LOCI FOR ASSOCIATION WITH
JUVENILE IDIOPATHIC ARTHRITIS
Anne Hinks1, Paul Martin1, Edward Flynn1, Steve Eyre1,
Jon Packham2, Anne Barton1, Jane Worthington1 and
Wendy Thomson1
1arc Epidemiology Unit, University of Manchester, Manchester, UK;
2Haywood Hospital, University Hospital of North Staffordshire, Stoke
on Trent, UK
Background: Autoimmune diseases affect about 1% of the population
and are caused by a combination of both genetic and environmental
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factors. It is now becoming clear that, despite the apparent clinical and
phenotypic differences of the autoimmune diseases, they share a
number of genetic risk factors. Of note there has been overlap
between type 1 diabetes (T1D) and celiac disease (CD). Many of these
loci are also susceptibility loci for rheumatoid arthritis (RA). There is
already strong evidence suggesting that JIA shares many susceptibility
loci with other autoimmune diseases, such as rheumatoid arthritis (RA),
type 1 diabetes and multiple sclerosis (MS). Therefore the aim of this
study was to test SNPs robustly associated with T1D or CD in a large
cohort of JIA cases and controls to investigate the overlap between
these diseases.
Methods: Sixteen SNPs that showed robust association (P<5 x 10-7)
with T1D and CD and had not been investigated previously in JIA were
genotyped in JIA cases (n¼1054) and healthy controls (n¼ 3129).
Genotype and allele frequencies were compared between cases with
JIA and controls using the Cochrane-Armitage trend test implemented
in PLINK and allelic odds ratios (ORs) and their 95% confidence
intervals (CIs) calculated.
Results: One SNP in the Lim domain containing preferred transloca-
tion partner in lipoma (LPP) gene showed significant association with
JIA (ptrend¼ 0.002 OR 1.18 95% CI 1.06-1.30). A second SNP,
rs653178, in ATXN2 showed a trend towards association with JIA
however this was not significant after correction for multiple testing
(ptrend¼0.02 OR 1.13 95% CI 1.02-1.25). SNPs in this region, have
previously shown evidence for association with JIA in a US cohort. A
SNP, rs17810546, in IL12A showed a significant allele frequency
difference (P¼ 0.03) between the subtypes and this was driven by a
strong association with enthesitis related arthritis (ERA) subtype
(ptrend¼0.005 OR 1.88 95% CI 1.2-2.94).
Conclusions: We present evidence for a novel JIA susceptibility locus,
LPP. LPP has a number of known functions including cell migration
and adhesion, has transcriptional activation capacity and has recently
been identified as a substrate of protein-tyrosine phosphatase 1B. We
present confirmatory evidence for association of the SH2B3/ATXN2/
c12orf30 region with JIA. In addition we identify a subtype specific
association of IL12A with ERA. All findings will require validation in
independent JIA data sets.
Acknowledgements: Childhood arthritis prospective study (CAPS),
UKRAG consortium and BSPAR study group.
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150. ASSOCIATION OF THE CCR5 GENE WITH JUVENILE
IDIOPATHIC ARTHRITIS
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Jon Packham2, Anne Barton1, Jane Worthington1 and
Wendy Thomson1
1arc Epidemiology Unit, University of Manchester, Manchester, UK;
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on Trent, UK
Background: CC chemokine receptor 5 (CCR5) has been shown
to be important in the recruitment of T helper cells to the synovium,
where they accumulate and drive the inflammatory process and
the consequent synovitis and joint destruction. A 32 base-pair
insertion/deletion variant (CCR5delta32) within the gene leads to
a frame shift and a non-functional receptor. CCR5delta32 has
been investigated for association with juvenile idiopathic arthritis
(JIA) with conflicting results. The aim of this study was to investigate
whether CCR5delta32 is associated with JIA in a UK population and
to combine our data with previously published studies in a meta-
analysis.
Methods: The CCR5delta32 variant was genotyped in JIA cases
(n¼ 1054) and healthy controls (n¼2390). Genotype and allele
frequencies were compared between cases with JIA and controls
using the Cochrane-Armitage trend test implemented in PLINK
and allelic odds ratios (ORs) and their 95% confidence intervals
(CIs) calculated. The Cochran-Mantel-Haenszel test was used
to perform a meta-analysis of the three cohorts and a test for
heterogeneity between cohorts was carried out using the Breslow-
Day test.
Results: CCR5delta32 was significantly associated with protection
from developing JIA, ptrend¼0.006, OR 0.79 95% CI 0.66-0.94. The
meta-analysis of all published case-control association studies
confirms the protective association with JIA (P¼0.001 OR 0.82 95%
CI 0.73-0.93).
Conclusions: We present evidence for a protective association of the
CCR5delta32 in a UK JIA case control cohort which is strengthened by
combining data from two previous studies by meta-analysis. Further
investigation into how this gene contributes to JIA pathogenesis is now
required. The CCR5delta32 is a functional variant determining the
number of receptors on the surface of T cells and its hypothesized that
the level of CCR5 expression could influence the migration of pro-
inflammatory T cells into the synovium and thus lead to susceptibility
to JIA.
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151. SHOULD WE BE LOOKING MORE CAREFULLY FOR
METHOTREXATE INDUCED LIVER DISEASE?
Mark Lloyd1, Raad Makadsi3, Aftab Ala2 and Patrick Connor2
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2Gastroenterology, Frimley Park Hospital, Frimley, UK;
3Rheumatology, East Surrey Hospital, Redhill, UK
Background: UK guidelines and a ‘Rheumatology’ editorial suggest
that liver function tests (LFTs) alone remain a satisfactory method for
methotrexate (MTX) monitoring in rheumatoid arthritis (RA). Recent
literature also suggests no difference in hepatotoxity between MTX
treated RA and psoriatic arthritis (PsA) patients. We describe 3 cases
of liver fibrosis / cirrhosis missed by conventional monitoring.
Methods: Case 1: 71 yr old female, RA 35 yrs. Presented 2005.
Previous breast cancer. Alcohol <1 unit/week. Rx MTX for 20 years,
up to 25mg weekly. Leflunomide (Lef) 10 mg od added 3 mths
previously. LFTs normal, P3NP 6.6. 2005-6 RA well controlled, normal
LFTs. Repeat P3NP 2006 11.7. Liver ultrasound (US): normal
echogenicity and hepatic and portal vein flow. Attempts to stop Lef
were unsuccessful and led to use of rescue depomedrone. Developed
diabetes. Sept 2007 LFTs normal, albumin 35. Feb 2008: admitted with
ascites, ALT 41, albumin 31, bilirubin 24. CT liver normal, US
suggested fatty change with normal portal flow. Biopsy showed
established cirrhosis on a background of steatohepatitis. MTX and Lef
stopped. June 2008: fatal pneumonia.
Case 2: 69 yr old male. RA 2007; previous type II diabetes Rx
insulin. On simvastatin. Alcohol <1 unit/week. eGFR 60. LFTs normal.
Rx MTX 12.5 mg/weekþ folic acid. July 2008 ALT 83: MTX # 10 mg,
Oct 2008 ALT 89: MTX #7.5 mg. Nov 2008 ALT 69. Dec 2008 - Aug
2009 ALT 70, 91, 67, 65, 52 (ie < x2 normal). Aug 2009 ALT 38, alb 27.
Sept 2008 ALT 85, albumin 22, INR 1.7.US: shrunken liver. Full liver
screen negative. Developed spontaneous bacterial peritonitis. Died
Sept 2009.
Results: Case 3: 63 yr old female, presented 1999. PsA diagnosed
1993, Rx MTX 7.5mg weekly. Alcohol <1 unit/week. 1996 ‘routine’
liver biopsy performed (i.e. after 3 yrs MTX), result missing. 1997 US
liver normal. Jan 1999: AST 69. Previous liver biopsy retrieved:
steatosis þ perivascular fibrosis. MTX stopped. LFTs normalized and
remain normal.
Conclusions: The risk of liver damage in some MTX treated RA
and PsA patients may be higher than we think. Patients remain
on MTX long term, may resume excess alcohol consumption and
may develop concommitant non alcoholic fatty liver disease and
steatohepatitis (NAFLD, NASH) during the course of their illness.
Polypharmacy (case 1) and diabetes (cases 1 and 2) may be further
risk factors. Normal LFTs and US may offer false reasurance.
However, minor elevations of liver enzymes may point towards
ongoing fibrosis (Case 2). P3NP is used in psoriasis but not in RA
because of the confounding factors of disease activity and joint
erosion. However, normal values may give some reassurance. US is
unreliable as a guide to fibrosis, but more sensitive scans, including
Fibroscan, offer promise. Our cases suggest that there may be at risk
MTX treated RA and PsA patients who require more detailed liver
monitoring.
Disclosure statement: All authors have declared no conflicts of
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152. RHEUMATOID ARTHRITIS AND BRONCHIECTASIS:
TREATMENT WITH RITUXIMAB
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Background: There is an increased prevalence of bronchietasis in
patients with Rheumatoid Arthritis (RA). RA with concomitant
Poster Viewing II Thursday 22 April 2010, 08:30-10:00 i89
 at Queens University of Belfast on December 11, 2012
http://rheum
atology.oxfordjournals.org/
D
ow
nloaded from
 
